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Identity 
Other names: NK2; NKA; NKNA; NPK; PPT; TAC2 




The TAC1 gene maps (Homo sapiens) to 
NC_000007.12 in the region between 97199311 and 
97207720 on the plus strand and spans 8410 bp. 
Transcription 
4 transcript variants: 
alpha (1134 bp); open reading frame from bp 247-582 
-lacks exon 6 
-encodes substance P on exon 3 
beta (1188 bp); open reading frame from bp 247-636 
-encodes the full-length version of Tac1 
-encodes substance P, neurokinin A, neuopeptide K 
delta (1089 bp); open reading frame from bp 247-537 
-lacks exons 4 and 6 
-encodes substance P on exon 3 
gamma (1143 bp); open reading frame from bp 247-
591 
-lacks exon 4 
-encodes substance P, neurokinin A 
Protein 
Note 
The TAC1 gene encodes multiple transcripts through 
post-translational modifications. Each encodes peptid s 
belonging to the tachykinin family of peptides. The 
major peptides produced from the TAC1 transcripts are 
substance P and neurokinin A. Others include  
neuropeptide K, and neuropeptide gamma. The 
tachykinins exert multiples functions such as 
neurotransmission, immune modulation and 
hematopoietic regulation. TAC1 encodes peptides that 
target nerve receptors, immune cells, stem cells, 
hematopoietic cells and smooth muscle cells. They 
function in vasodilatory responses; act as secretagogues 
and can induce behavioral responses. 
Description 
4 peptides: 
alpha: 111 aa 
-comprises substance P 
beta: 129 aa 
-comprises substance P, neurokinin A, neuropeptide K 
delta: 96 aa 
-comprises substance P 
gamma: 114 aa 
-comprises neuropeptide gamma, substance P, 
neurokinin A. 
Expression 
Expressed by various immune and neuronal cells. 
TAC1 expression in the setting of osteoarthritis can be 
induced by mechanical stimulation (Howard et al., 
2008). 
TAC1 expression is also regulated by microRNAs in 
neurons derived from human mesenchymal stem cells 
(Greco et al., 2007). This occurs by binding of miRNA-
13-a, miRNA206 and miRNA302a to the Tac1 3'UTR. 
HIV1 infection resulted in increase production of 
TAC1 peptide (substance P). The source of substance P 
has been identified as monocytes-derived macrophages 
from placenta cord blood and adult peripheral blood. 
The production of substance P correlates with HIV 1 
infection (Douglas et al., 2002). 
Localisation 
Secreted peptide. 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(5)  486 
Function 
TAC1 peptides function in both pathologic and 
physiologic processes. These include hematopoiesis, 
gastrointestinal secretory processes, respiratory 
patterns, calcium signaling, neuropeptide signaling, 
pain, synaptic transmission, insemination (Murthy et 
al., 2008; David et al., 2009); inflammatory response, 
autism, and pulmonary infection (Marui et al., 2007; 
Grissell et al., 2007). In normal respiratory 
development, TAC1 appears to be a crucial gene, 
exerting plasticity during development (Berner et al.,
2007). 
TAC1 is involved in hematopoietic regulation. The 
mRNA is targeted by RNA-binding protein that confers 
translational control, which could be negatively 
regulated by cytokines with hematopoietic stimulator 
properties (Murthy et al., 2008). TAC1 has been 
implicated in macrophage and monocyte functions 
(Chernova et al., 2009). 
Homology 
Homo sapiens TAC1 shares sequence homology with 




A gene expression signature for breast cancer has been
shown to involve TAC1 (Ellsworth et al., 2009). 
Prognosis 
TAC1 expression occurs in breast cancer and is directly 
proportional to aggressiveness of the cancer and thus, 
TAC1 may also be a prognostic factor in breast cancer 
(Ellsworth et al., 2009; Reddy et al., 2009). 
Oncogenesis 
TAC1 expression favors breast cancer cell entry into
the bone marrow during stage IV disease (Reddy et al., 
2009). TAC1 regulates the interaction between 
CXCL12 and its receptor, CXCR4 in the interaction 
between breast cancer and mesenchymal stem cells 
(Corcoran et al., 2008). 
The TAC1 gene products, substance P and neurokinin 
A, and neurokinin receptor antagonists have been 
shown to have anti-proliferative effects on breast 




Substance P, the major peptide encoded by the TAC1 
gene, is mitogenic to colon cancer. Its action on the 
cancer cells appears to be autocrine since NK1 
antagonist has been shown to mediate anti-tumor  
activity (Rosso et al., 2008). On the other hand, 
Substance P also enhances the expansion of 
lymphokine-activated killer cells against colon caner 
cells (Flageole et al., 1992). These two properties of 
substance P appear paradoxical. Thus, targeted therapy 
will need to balance the immune-enhancing effects 
with the tumor promoting functions of substance. 
Prognosis 
In Dukes stage A/B cancers, TAC1 methylation levels 
were significantly higher than in Dukes stage C/D 
cancers (Mori et al., 2006). 
Oncogenesis 
TAC1 was found to be silenced via promoter 
methylation in primary colon cancer and may lead to 
early stage carcinogenesis by aiding tumor cells to 
escape immune surveillance and autocrine growth-
inhibitory signaling (Mori et al., 2006). 
Esophageal cancer 
Prognosis 
Promoter hypermethylation of TAC1 confers poor 
prognosis in esophageal cancer (Jin et al., 2007). 
Oncogenesis 
TAC1 promoter hypermethylation has been suggested 
to be a putative marker for esophageal carcinoma (Jin 
et al., 2007). 
Gastric adenocarcinoma 
Oncogenesis 
Promoter hypermethylation of TAC1 has also been 
found in gastric adenocarcinoma (David et al., 2009). 
Multiple sclerosis 
Note 
The genetic region surrounding TAC1 may be unstable 
and has been associated with increased susceptibility to 
multiple sclerosis (Vandenbroeck et al., 2002). 
Narcolepsy 
Note 
TAC1 and other related peptides have been associated 
with narcolepsy. Stimulation by amphetamines 
promotes increased TAC1 expression (Lindberg et al., 
2007). 
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